maprotiline has been researched along with propranolol in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (13.79) | 18.7374 |
| 1990's | 1 (3.45) | 18.2507 |
| 2000's | 10 (34.48) | 29.6817 |
| 2010's | 14 (48.28) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Bacsó, Z; Cianfriglia, M; Fenyvesi, F; Goda, K; Kappelmayer, J; Lustyik, G; Nagy, H; Szabó, G; Szilasi, M | 1 |
| Johans, C; Kinnunen, PK; Söderlund, T; Suomalainen, P | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Faller, B; Trunzer, M; Zimmerlin, A | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Atzpodien, EA; Csato, M; Doessegger, L; Fischer, H; Lenz, B; Schmitt, G; Singer, T | 1 |
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Delini-Stula, A; Radeke, E; Vassout, A | 1 |
| Schultheiss, A; Starke, K; Szabo, B | 1 |
| Moral, L; Saiz-Ruiz, J | 1 |
| Lesar, T; Tollefson, G | 1 |
| Evans, DL; Nemeroff, CB | 1 |
| Amelin, AV; Ignatov, IuD; Skoromets, AA | 1 |
| Hajhashemi, V; Minaiyan, M; Movahedian, A; Sadeghi, H; Talebi, A | 1 |
2 review(s) available for maprotiline and propranolol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Current views on migraine and anti-migraine preparations].
Topics: Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; Amitriptyline; Analgesics; Analgesics, Non-Narcotic; Antidepressive Agents; Aza Compounds; Brain; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Clonidine; Fluoxetine; Humans; Imidazoles; Maprotiline; Methysergide; Migraine Disorders; Mutation; Pizotyline; Placebos; Propranolol; Research; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Sympatholytics; Vasoconstrictor Agents | 2003 |
27 other study(ies) available for maprotiline and propranolol
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
Topics: Adenosine Triphosphatases; Animals; Anti-Bacterial Agents; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Calcium Channel Blockers; Cyclosporine; Detergents; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluoresceins; Humans; Ivermectin; Mice; NIH 3T3 Cells; Substrate Specificity | 2004 |
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
Topics: Blood-Brain Barrier; Lipid Bilayers; Micelles; Permeability; Pharmaceutical Preparations; Structure-Activity Relationship; Surface Properties | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation.
Topics: Chromatography, Liquid; Drug Design; Humans; Likelihood Functions; Microsomes, Liver; Pharmacokinetics; Tandem Mass Spectrometry | 2009 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
Topics: Animals; Cattle; Cells, Cultured; Computer Simulation; Cornea; Drug-Related Side Effects and Adverse Reactions; Fibroblasts; Lipidoses; Lysosomal Storage Diseases; Models, Molecular; Pharmaceutical Preparations; Phospholipids; Structure-Activity Relationship; Thermodynamics | 2012 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Some aspects of the psychopharmacological activity of maprotiline (Ludiomil): effects of single and repeated treatments.
Topics: 5-Hydroxytryptophan; Amitriptyline; Animals; Anthracenes; Behavior, Animal; Body Temperature; Clomipramine; Depression, Chemical; Escape Reaction; Haplorhini; Head; Imipramine; Maprotiline; Mice; Muscle Contraction; Phenobarbital; Propranolol; Rats; Reserpine; Shrews | 1978 |
The noradrenaline uptake inhibitor, (+)-oxaprotiline, but not the inactive enantiomer, (-)-oxaprotiline, inhibits sympathetic nerve activity in the rabbit: involvement of adrenoceptors.
Topics: Animals; Blood Pressure; Clonidine; Drug Interactions; Ganglia, Sympathetic; Heart Rate; Kidney; Maprotiline; Neurotransmitter Uptake Inhibitors; Norepinephrine; Prazosin; Propranolol; Rabbits; Receptors, Adrenergic, alpha; Stereoisomerism; Sympathetic Nervous System; Yohimbine | 1991 |
Delirium induced by association of propranolol and maprotiline.
Topics: Adult; Anthracenes; Anxiety Disorders; Delirium; Drug Therapy, Combination; Humans; Male; Maprotiline; Propranolol | 1988 |
Effect of propranolol on maprotiline clearance.
Topics: Adult; Anthracenes; Depressive Disorder; Drug Interactions; Humans; Hydroxylation; Liver Circulation; Male; Maprotiline; Propranolol | 1984 |
Concurrent use of antidepressants and propranolol: case report and theoretical considerations.
Topics: Anthracenes; Depressive Disorder; Drug Therapy, Combination; Humans; Male; Maprotiline; Middle Aged; Propranolol; Tremor | 1983 |
Central and peripheral anti-inflammatory effects of maprotiline on carrageenan-induced paw edema in rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Anti-Inflammatory Agents; Antidepressive Agents, Second-Generation; Carrageenan; Edema; Hormone Antagonists; Indomethacin; Injections, Spinal; Male; Maprotiline; Mifepristone; Naloxone; Narcotic Antagonists; Prazosin; Propranolol; Rats; Rats, Wistar; Yohimbine | 2010 |